Precision BioSciences presented late-breaking data from its ELIMINATE-B study showing something no chronic hepatitis B therapy has cleanly demonstrated in patients: direct elimination of cccDNA, the stable reservoir of viral DNA that hides in the liver and makes the infection so hard to cure. New liver-biopsy data indicated that PBGENE-HBV, through its primary editing mechanism, produced roughly a 1-log, or tenfold, reduction in cccDNA-derived transcripts. Alongside that, 100% of patients dosed, fifteen in total, showed substantial declines in hepatitis B surface antigen across all dose levels, and the company reported loss of the pgRNA biomarker in every patient who had it detectable at baseline. Precision was also added to the Russell 2000 in the late-June reconstitution.
The reason this matters is mechanistic. Existing antivirals suppress hepatitis B but do not clear the cccDNA reservoir, which is why patients relapse. A therapy that physically deletes that reservoir is the difference between control and a potential functional cure. That is the bull case in one sentence.
The honest caveat
A tenfold reduction in cccDNA-derived transcripts is a real first-in-human proof of mechanism. It is also a first step, not a knockout. The candid concern, which we would rather state than bury, is that the doses tested in patients so far sit below the levels that drove greater than 90% antigen reduction in animal models. The open question is whether pushing the dose higher translates the mechanism into the depth and durability of effect a functional cure would require, and whether the safety profile holds as it climbs.
This is the gap between an exciting mechanism and an approvable product, and it is exactly where gene-editing stories tend to get re-rated in both directions.
The other side
Precision is clinical-stage and loss-making, and an in-vivo gene editor for a chronic viral disease is a long, capital-intensive road with regulatory novelty at every turn. The 100% HBsAg response is encouraging, but the follow-up is early and durability is unproven. As with every name at this stage, financing and dilution belong in the risk column.
- Direct cccDNA elimination. First human biopsy evidence of cutting the reservoir that makes hepatitis B incurable, with HBsAg declines in all fifteen patients.
- Dose-response gap. Human doses sit below the levels that drove greater than 90% antigen reduction in animals; depth and durability are unproven.
- Clinical-stage risk. Losses continue, the regulatory path for an in-vivo editor is novel, and financing is a live consideration.
What to watch
The next PBGENE-HBV dose cohorts are the whole story: whether higher doses deepen the cccDNA and antigen effect while staying safe. That is the data that decides whether this is a functional-cure platform or a promising mechanism that could not reach escape velocity.
Disclosure
This article is independent editorial content and reflects the author's opinion and analysis as of the date of publication. It is not investment advice and should not be relied on as the basis for any investment decision. MicroCap Desk and its contributors received no compensation of any kind — cash, securities, or otherwise — from any company mentioned, or from any third party, in connection with this article. The author holds no position in any security mentioned. Information is drawn from sources believed reliable but is not guaranteed accurate or complete. Microcap securities carry a high risk of loss. Do your own research. See our full Disclosure.
